Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1
Standard
Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1. / Kerl, Kornelius; Moreno, Natalia; Holsten, Till; Ahlfeld, Julia; Mertins, Julius; Hotfilder, Marc; Kool, Marcel; Bartelheim, Kerstin; Schleicher, Sabine; Handgretinger, Rupert; Schüller, Ulrich; Meisterernst, Michael; Frühwald, Michael C.
In: INT J CANCER, Vol. 135, No. 4, 15.08.2014, p. 989-95.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1
AU - Kerl, Kornelius
AU - Moreno, Natalia
AU - Holsten, Till
AU - Ahlfeld, Julia
AU - Mertins, Julius
AU - Hotfilder, Marc
AU - Kool, Marcel
AU - Bartelheim, Kerstin
AU - Schleicher, Sabine
AU - Handgretinger, Rupert
AU - Schüller, Ulrich
AU - Meisterernst, Michael
AU - Frühwald, Michael C
N1 - © 2014 UICC.
PY - 2014/8/15
Y1 - 2014/8/15
N2 - Rhabdoid tumors are highly aggressive tumors occurring in infants and very young children. Despite multimodal and intensive therapy prognosis remains poor. Molecular analyses have uncovered several deregulated pathways, among them the CDK4/6-Rb-, the WNT- and the Sonic hedgehog (SHH) pathways. The SHH pathway is activated in rhabdoid tumors by GLI1 overexpression. Here, we demonstrate that arsenic trioxide (ATO) inhibits tumor cell growth of malignant rhabdoid tumors in vitro and in a mouse xenograft model by suppressing Gli1. Our data uncover ATO as a promising therapeutic approach to improve prognosis for rhabdoid tumor patients.
AB - Rhabdoid tumors are highly aggressive tumors occurring in infants and very young children. Despite multimodal and intensive therapy prognosis remains poor. Molecular analyses have uncovered several deregulated pathways, among them the CDK4/6-Rb-, the WNT- and the Sonic hedgehog (SHH) pathways. The SHH pathway is activated in rhabdoid tumors by GLI1 overexpression. Here, we demonstrate that arsenic trioxide (ATO) inhibits tumor cell growth of malignant rhabdoid tumors in vitro and in a mouse xenograft model by suppressing Gli1. Our data uncover ATO as a promising therapeutic approach to improve prognosis for rhabdoid tumor patients.
KW - Animals
KW - Antineoplastic Agents
KW - Apoptosis
KW - Arsenicals
KW - Cell Cycle
KW - Cell Proliferation
KW - Computational Biology
KW - Gene Expression Profiling
KW - Gene Expression Regulation
KW - Gene Expression Regulation, Neoplastic
KW - Hedgehog Proteins
KW - Humans
KW - Kruppel-Like Transcription Factors
KW - Mice
KW - Mice, SCID
KW - Neoplasm Transplantation
KW - Oxides
KW - Prognosis
KW - Rhabdoid Tumor
KW - Signal Transduction
KW - Transcription Factors
KW - Zinc Finger Protein GLI1
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
U2 - 10.1002/ijc.28719
DO - 10.1002/ijc.28719
M3 - SCORING: Journal article
C2 - 24420698
VL - 135
SP - 989
EP - 995
JO - INT J CANCER
JF - INT J CANCER
SN - 0020-7136
IS - 4
ER -